



Fermiscan Holdings Limited
ABN 51 000 689 725

Level 7
48 Hunter Street
Sydney NSW 2000

t. +61 2 9245 4460
f. +61 2 9209 4353

www.fermiscan.com.au

ASX ANNOUNCEMENT

29 July 2009

Pre-commercialisation Pilot with General Practitioners

Fermiscan is pleased to announce the commencement of a pre-commercialisation pilot for the Fermiscan Breast Cancer Test in Australia.

The pilot program is aimed at gathering information on the use of the test in the clinical setting of General Practice. The Fermiscan Test will be used as an adjunct to clinical breast examination for patients where there is a defined medical need for this type of screening.

The pilot will be conducted with 20 General Practitioner groups in Sydney as a commercial service in which patients will be charged \$200 for the test. The doctor will collect a hair sample from a patient and forward it to Fermiscan for processing and analysis. The result will be reported back to the doctor within 14 working days.

This pilot program is designed as a preliminary step and guide to the planned commercialisation of the Fermiscan Breast Cancer Test. In working closely with the participating General Practitioners, the pilot will assist Fermiscan to optimise the collection process of viable hair samples and the subsequent medical interpretation of the results to ensure appropriate counselling or follow up examinations with patients in a commercial setting.

The General Practitioner is the ideal medical professional to deliver this test, based on current screening practices, patients' requirements for counselling and the need for medical expertise in diagnosis. The General Practitioner has an integral role in administering preventative medical intervention, which is the main focus for breast cancer prevention. Given the current emphasis of General Practitioners on the early detection of breast cancer, Fermiscan believes that General Practice provides the ideal setting for implementation of the Fermiscan Breast Cancer Test whilst ensuring the needs and well-being of patients are safeguarded.

Fermiscan will closely monitor the use of the Fermiscan Test and will provide assistance to the General Practitioner regarding the test results in order that the results may be better incorporated into their patient's ongoing care.

Gary Garton
Chairman

Visit Fermiscan's website at www.fermiscan.com.au

About Fermiscan

Fermiscan's principal interest is the commercialisation of an innovative non-invasive diagnostic test for the detection of breast cancer.

The Fermiscan Breast Cancer Test is based on the discovery by an Australian scientist that a change can be detected in the molecular structure of hair from women with breast cancer and this change can be identified by using diffraction of X-rays generated in a synchrotron.

Fermiscan completed a major clinical trial of the Fermiscan Test in May 2008, with sensitivity (ability to accurately detect cancer) of 74% in women under 70, and with a higher sensitivity for younger women; and specificity (ability to accurately detect the absence of cancer - negative predictive value) of 99.5%.

Fermiscan is developing opportunities to licence and sell the Fermiscan Test internationally, particularly in Australia, Europe, Japan, South East Asia, and the United States.

Fermiscan owns and operates the Sydney Breast Clinic, one of the largest diagnostic breast clinics in Australia that for more than 30 years has been caring for over 10,000 women annually.

With major clinical trials successfully concluded, commercialisation of the Fermiscan Test is progressing to plan in 2009.

Recent announcements

- Patents granted in Japan and European Community countries
- Exclusive option agreement to licence the Fermiscan Test to Hitachi Chemical in Japan and Korea granted in March 2009
- Italian independent study with sensitivity (ability to accurately detect cancer) of 83% and specificity (ability to accurately detect the absence of cancer) of 76%
- Independent European multi-centre trial of the Fermiscan Test is underway and these should support commercialisation in Italy and Europe
- European CE Mark registration of the Fermiscan Test completed in July 2009
- Australian Synchrotron agreement signed in February 2009 securing beamline access for two years
- Named 2008 'Australian Innovator of the year' at the Austrade sponsored annual 'Innovation Day Shoot Out' competition in New York

Fermiscan is a member of the Australian Technology Showcase, a national program aimed at promoting and developing export markets for innovative technology based products. Fermiscan has received support from the NSW Department of State and Regional Development through its various programs such as BioBusiness and BioFirst

Visit Fermiscan's website at www.fermiscan.com.au

Visit Sydney Breast Clinic's website at www.sydneybreastclinic.com.au